Eli Lilly anticipates that the shortage of its weight-loss drug tirzepatide will be resolved in the U.S. in the coming days, according to a Bloomberg News report citing an interview with the company's CEO, David Ricks. Tirzepatide has been in limited supply since late 2022, as indicated by the FDA website.

The FDA declined to provide further comments beyond the information available on its drug shortages list, and Lilly did not immediately respond to a request for comment. The agency typically assesses whether all backorders for a drug have been filled and if the supply is meeting or exceeding demand before removing it from the shortage list.

In April, Lilly stated that it expects the supply of tirzepatide to remain tight in the near and midterm as the company works to increase production capacity. Lilly and its Danish competitor, Novo Nordisk, are both striving to meet the growing demand in the weight-loss drug market, which is estimated to reach approximately $150 billion by the early 2030s.